Our top coverage from this year’s Revolutionizing Atopic Dermatitis (RAD) conference highlighted the evolving therapy landscape for patients with AD.
Our top coverage featuring this year’s Revolutionizing Atopic Dermatitis (RAD) 2023 conference surrounded the unique and oftentimes challenging treatment landscape for patients with AD, as well as the disparities within dermatologic patient care that still need to be addressed.
These are your top RAD 2023 conference highlights. Click here for all our coverage from this conference.
Dr Larry Eichenfield: A Changing Therapy Landscape Provides More Options for Infants With AD
In this interview, Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine, and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, shared key points he hoped physicians took away from his session on choosing the right treatments and therapies for AD in infants.
Posters Show Ruxolitinib Cream to Be Both Effective and Safe for Treating AD
Two posters provided insights into the safety and efficacy of ruxolitinib cream for AD and chronic hand dermatitis (CHD). The first poster analyzed safety reports during the first year of market approval, finding no systemic adverse events and a low incidence of application site reactions, indicating that ruxolitinib cream was well tolerated. The second poster presented interim results of a study testing the efficacy of ruxolitinib 1.5% cream in CHD, showing promising results with reductions in Investigator Global Assessment scores, hand eczema severity index, and itch levels after 4 weeks of treatment.
Symposium Highlights New Research on JAK, PDE-4 Inhibitors
In this symposium, Dr Eichenfield discussed innovations in nonsteroid topical therapies for AD, highlighting the efficacy and safety of topical ruxolitinib 1.5% cream in patients 12 years and older. Meanwhile, Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology and director of clinical research and contact dermatitis at The George Washington University School of Medicine and Health Sciences in Washington, DC, presented insights into oral Janus kinase (JAK) inhibitors for AD.
Panel Focuses on Burgeoning Therapies in Atopic Dermatitis
This symposium featured a panel discussing upcoming treatments for AD, including nonsteroidal topicals and biologics. Melinda Gooderham, MD, MSc, FRCPC, reviewed medications like tapinarof and roflumilast expected by 2024, presenting positive results from phase 3 trials, while David Rosmarin, MD, highlighted early-stage developments, emphasizing promising outcomes in treatments targeting microbial, itch, and adaptive immune system pathways for AD.
Disparities in AD Treatment: What Can Be Done?
The final symposium at RAD 2023 addressed disparities in care for patients of color with AD. Panelists, including Andrew Alexis, MD, MPH, FAAD, vice chair for diversity and inclusion for the Department of Dermatology and a dermatologist at the Center for Diverse Skin Complexions at Weill Cornell Medicine in New York City, highlighted the higher prevalence of diagnosed AD among patients of color and the impact on their quality of life.
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen